News

Dazucorilant, an oral cortisol modulator being developed by Corcept Therapeutics, didn’t significantly slow disease progression in people with amyotrophic lateral sclerosis (ALS) over a placebo, meaning it failed to meet the primary goal of the DAZALS Phase 2 clinical trial. The study (NCT05407324), which tested dazucorilant doses…

Bravyl (oral fasudil), an experimental therapy Woolsey Pharmaceuticals is developing for amyotrophic lateral sclerosis (ALS), significantly reduced the spread of toxic TDP-43 protein clumps in a cell model of the disease. New data was presented at the University of Denver during the International Symposium on ALS/MND, which took…

Specialists diagnose amyotrophic lateral sclerosis (ALS) twice as fast as general neurologists, research led by the ALS Association in collaboration with leading ALS clinicians shows.  The average time for ALS or neuromuscular specialists to diagnose ALS…

People with amyotrophic lateral sclerosis (ALS) are more likely than those without the neurodegenerative disease to have grown up in rural areas, have younger parents, and have lower levels of education, a new study found. These results suggest that events and conditions in early life may be potential environmental…

The U.S. Food and Drug Administration (FDA) signaled that it may be willing to consider granting accelerated approval to CNM-Au8 to treat amyotrophic lateral sclerosis (ALS), based on data from clinical trials and ongoing expanded access programs. The therapy’s developer, Clene, said it will put together an…

MN-166 (ibudilast), an investigational oral treatment for amyotrophic lateral sclerosis (ALS), appears to slow disease progression over up to one year of use, according to an analysis of data in an ongoing Phase 2b/3 clinical trial. The interim analysis, required under the study’s design, looked into how well…

Quralis has dosed the first patient in a Phase 1 clinical trial testing QRL-101 — its treatment candidate for reducing nerve cell overactivation in amyotrophic lateral sclerosis (ALS) and thus potentially slowing disease progression — in adults with ALS. The proof-of-mechanism QRL-101-04 trial (NCT06714396) is still enrolling…

MaaT033, an experimental oral therapy for improving the gut microbiome — the collection of microbes, including bacteria, in the human gut — was deemed safe and well tolerated in people with amyotrophic lateral sclerosis (ALS) after two months of dosing. That’s according to a new analysis from an independent…

The technology company Unlearn is teaming up with APST Research to create “digital twins” to support clinical trials for amyotrophic lateral sclerosis (ALS). Clinical data from more than 8,000 ALS patients in APST’s database will be fed into Unlearn’s Digital Twin Generator (DTG), an artificial intelligence…

Twice-daily treatment with PTC Therapeutics’ oral candidate utreloxastat failed to significantly slow disease progression in adults with amyotrophic lateral sclerosis (ALS) in a global, placebo-controlled Phase 2 clinical trial. The results of CardinALS (NCT05349721) showed that, while the therapy was generally safe, it failed to meet its…